2014

# USP 37 THE UNITED STATES PHARMACOPEIA

# NF 32 THE NATIONAL FORMULARY

Volume 1

*By authority of the United States Pharmacopeial Convention*
*Prepared by the Council of Experts and its Expert Committees*

*Official from May 1, 2014*

The designation on the cover of this publication, "USP NF 2014," is for ease of identification only. The publication contains two separate compendia: *The United States Pharmacopeia*, Thirty-Seventh Revision, and *The National Formulary*, Thirty-Second Edition.

THE UNITED STATES PHARMACOPEIAL CONVENTION
12601 Twinbrook Parkway, Rockville, MD 20852

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

## SIX-MONTH IMPLEMENTATION GUIDELINE

The *United States Pharmacopeia–National Formulary* and its supplements become official **six months** after being released to the public. The *USP–NF*, which is released on November 1 of each year, becomes official on May 1 of the following year. This six-month implementation timing gives users more time to bring their methods and procedures into compliance with new and revised *USP–NF* requirements.

The table below describes the official dates of the *USP–NF* and its supplements. The 2013 *USP 36–NF 31*, and its supplements, *Interim Revision Announcements (IRAs)* and *Revision Bulletins* to that edition, will be official until May 1, 2014, at which time the *USP 37–NF 32* becomes official.

| Publication | Release Date | Official Date | Official Until |
|---|---|---|---|
| *USP 37–NF 32* | November 1, 2013 | May 1, 2014 | May 1, 2015 (except as superseded by supplements, *IRAs*, and *Revision Bulletins*) |
| *First Supplement to the USP 37–NF 32* | February 1, 2014 | August 1, 2014 | May 1, 2015 (except as superseded by *Second Supplement*, *IRAs*, and *Revision Bulletins*) |
| *Second Supplement to the USP 37–NF 32* | June 1, 2014 | December 1, 2014 | May 1, 2015 (except as superseded by *IRAs* and *Revision Bulletins*) |
| *USP 38–NF 33* | November 1, 2014 | May 1, 2015 | May 1, 2016 (except as superseded by supplements, *IRAs*, and *Revision Bulletins*) |

The table below gives the details of the *IRAs* that will apply to *USP 37–NF 32*.

| IRA | PF Posting Date | Comment Due Date | IRA Posting Date | IRA Official Date |
|---|---|---|---|---|
| 40(1) | January 2, 2014 | March 31, 2014 | May 30, 2014 | July 1, 2014 |
| 40(2) | March 3, 2014 | May 31, 2014 | July 31, 2014 | September 1, 2014 |
| 40(3) | May 1, 2014 | July 31, 2014 | September 26, 2014 | November 1, 2014 |
| 40(4) | July 1, 2014 | September 30, 2014 | November 26, 2014 | January 1, 2015 |
| 40(5) | September 2, 2014 | November 30, 2014 | January 30, 2015 | March 1, 2015 |
| 40(6) | November 3, 2014 | January 31, 2015 | March 27, 2015 | May 1, 2015 |

*Revision Bulletins* published on the USP website become official on the date specified in the *Revision Bulletin*.

## NOTICE AND WARNING

*Concerning U.S. Patent or Trademark Rights*—The inclusion in *The United States Pharmacopeia* or in the *National Formulary* of a monograph on any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner.

*Concerning Use of* USP *or* NF *Text*—Attention is called to the fact that *USP* and *NF* text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Secretary of the USPC Board of Trustees.

Copyright © 2013 The United States Pharmacopeial Convention
12601 Twinbrook Parkway, Rockville, MD 20852

*All rights reserved.*

ISSN: 0195-7996

ISBN: 978-1-936424-22-1

Printed in the United States by United Book Press, Inc., Baltimore, MD

Find authenticated court documents without watermarks at docketalarm.com.

Ammonium *(continued)*
formate, 1376
glycyrrhizate, 5852
hydroxide, 1376
hydroxide 6 N, 1376
molybdate, 1376, 1765
molybdate injection, 1766
molybdate TS, 1446
nitrate, 1376
nitrate, ceric TS, 1447
nitrate TS, silver, 1451
oxalate, 1376
oxalate TS, 1446
persulfate, 1376
phosphate, 5853
phosphate, dibasic, 1376
phosphate, dibasic, TS, 1446
phosphate, monobasic, 1376
polysulfide TS, 1446
pyrrolidinedithiocarbamate, 1376
pyrrolidinedithiocarbamate, saturated, TS, 1446
reineckate, 1376
reineckate TS, 1446
sulfamate, 1376
sulfate, 1376, 5854
sulfate, cupric TS, 1447
sulfate, ferric TS, 1448
sulfide TS, 1446
thiocyanate, 1376
thiocyanate, tenth-normal (0.1 N), 1454
thiocyanate TS, 1446
vanadate, 1376
vanadate TS, 1446
Amobarbital sodium, 1767
for injection, 1767
and secobarbital sodium capsules, 4667
Amodiaquine, 1767
hydrochloride, 1768
hydrochloride tablets, 1769
Amoxapine, 1770
tablets, 1770
Amoxicillin, 1771
boluses, 1773
capsules, 1774
and clavulanate potassium for oral suspension, 1778
and clavulanate potassium tablets, 1779
and clavulanic acid extended-release tablets, 1780
for injectable suspension, 1775
intramammary infusion, 1774
oral suspension, 1775
for oral suspension, 1775
tablets, 1776
tablets for oral suspension, 1777
Amphetamine
sulfate, 1783
sulfate tablets, 1784
Amphotericin B, 1785
cream, 1785
for injection, 1786
lotion, 1786
ointment, 1786
Ampicillin, 1786
boluses, 1792
capsules, 1792
for injectable suspension, 1795
for injection, 1794
and probenecid for oral suspension, 1797
sodium, 1798
soluble powder, 1794
and sulbactam for injection, 1799
for oral suspension, 1795
tablets, 1796
Amprolium, 1800
soluble powder, 1801
oral solution, 1801
Amyl
acetate, 1377
alcohol, 1377
nitrite, 1802
nitrite inhalant, 1802
α-Amylase, 1377
Amylene hydrate, 5855
*tert*-Amyl alcohol, 1377
Anagrelide
capsules, 1804
hydrochloride, 1803
Analysis of Biological Assays ⟨1034⟩, 603
Analytical data—interpretation and treatment ⟨1010⟩, 515
Analytical instrument qualification ⟨1058⟩, 747
Anastrozole, 1806
Ancillary materials for cell, gene, and tissue-engineered products ⟨1043⟩, 619
Andrographis, 5245
extract, powdered, 5248
powdered, 5247
Anethole, 5855
(*E*)-Anethole, 1377
Angustifolia
extract, powdered echinacea, 5350
powdered echinacea, 5346


## Anhydrous


acetone, 1372
alumina, 1377
barium chloride, 1377
calcium chloride, 1377
calcium phosphate, dibasic, 2098
citric acid, 2367
cupric sulfate, 1377
dibasic sodium phosphate, 1377
magnesium perchlorate, 1377
magnesium sulfate, 1377
methanol, 1377
potassium carbonate, 1377
sodium acetate, 1377
sodium carbonate, 1377
sodium phosphate, monobasic, 1429
sodium sulfate, 1377
sodium sulfite, 1377

Anileridine, 1807
hydrochloride, 1808
hydrochloride tablets, 1809
injection, 1808
Aniline, 1377
blue, 1377
sulfate, 1377
Anion-exchange resin
50- to 100-mesh, styrene-divinylbenzene, 1377
strong, lightly cross-linked, in the chloride form, 1377
styrene-divinylbenzene, 1377
*p*-Anisaldehyde, 1378
Anise oil, 5856
*p*-Anisidine, 1378
Anisole, 1378
Annotations
to *NF 32*, 5820
to *USP 37*, xl
Antazoline phosphate, 1810
Anthracene, 1378
Anthralin, 1810
cream, 1811
ointment, 1812
Anthrax vaccine adsorbed, 1813
Anthrone, 1378
TS, 1446
Antibiotics—microbial assays ⟨81⟩, 77
Anticoagulant
citrate dextrose solution, 1815
citrate phosphate dextrose solution, 1816
citrate phosphate dextrose adenine solution, 1817
heparin solution, 3228
sodium citrate solution, 1819
Anti-D reagent, 1378
Anti-D ($Rh_o$) reagent, 1378
Anti-factor Xa and anti-factor IIa assays for unfractionated and low molecular weight heparins ⟨208⟩, 152
Antifoam reagent, 1378
Antihuman globulin reagent, 1378
Antimicrobial
agents—content ⟨341⟩, 179
effectiveness testing ⟨51⟩, 52
Antimony
pentachloride, 1378
potassium tartrate, 1819
sodium tartrate, 1820
trichloride, 1379
trichloride TS, 1446
Antipyrine, 1820
and benzocaine otic solution, 1821
benzocaine, and phenylephrine hydrochloride otic solution, 1822
Antithrombin III, 1379
human, 1822
Apomorphine hydrochloride, 1824
tablets, 1825
Apparent intrinsic dissolution—dissolution testing procedures for rotating disk and stationary disk ⟨1087⟩, 831
Applications of nuclear magnetic resonance spectroscopy ⟨1761⟩, 1284
Application of water activity determination to nonsterile pharmaceutical products ⟨1112⟩, 925
Apraclonidine
hydrochloride, 1825
ophthalmic solution, 1826
Aprobarbital, 1379
Aprotinin, 1827
injection, 1829
Arcitumomab injection, technetium Tc 99m, 4844
Arginine, 1829
capsules, 5250
hydrochloride, 1830
hydrochloride injection, 1831
tablets, 5250
Aripiprazole, 1831
Aromatic
castor oil, 2175
elixir, 5856
Arsanilic acid, 1832


Index

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

This material may be protected by Copyright law (Title 17 U.S. Code)



**Burets** *(Continued)*

| Subdivisions, mL | 0.02 | 0.1 | 0.1 |
|---|---|---|---|
| Limit of error, mL | 0.02 | 0.05 | 0.05 |

## 〈41〉 BALANCES

This chapter states the requirements for balances used for materials that must be accurately weighed (see *General Notices, 8.20*). Unless otherwise specified, when substances must be "accurately weighed", the weighing shall be performed using a balance that is calibrated over the operating range and meets the requirements defined for repeatability and accuracy. For balances used for other applications, the balance repeatability and accuracy should be commensurate with the requirements for its use.

For discussion of the theoretical basis of these requirements, see general information chapter *Weighing on an Analytical Balance* 〈1251〉, which may be a helpful—but not mandatory—resource.

### REPEATABILITY

Repeatability is assessed by weighing one test weight NLT 10 times. [NOTE—The test weight must be within the balance's operating range, but the weight need not be calibrated. Because repeatability is virtually independent of sample mass within the balance's capacity, use of a small test weight, which may be difficult to handle, is not required.]

Repeatability is satisfactory if two times the standard deviation of the weighed value, divided by the nominal value of the weight used, does not exceed 0.10%. If the standard deviation obtained is less than 0.41*d*, where *d* is the scale interval, replace this standard deviation with 0.41*d*. In this case, repeatability is satisfactory if two times 0.41*d*, divided by the nominal value of the weight used, does not exceed 0.10%.

### ACCURACY

The accuracy of a balance is satisfactory if its weighing value, when tested with a suitable weight(s), is within 0.10% of the test weight value.

A test weight is suitable if it has a mass between 5% and 100% of the balance's capacity. The test weight's maximum permissible error (mpe), or alternatively its calibration uncertainty, shall be NMT one-third of the applied test limit of the accuracy test. [NOTE—Applicable standards are the following: ASTM E617 (available from http://www.astm.org) and OIML R 111 (available from http://www.oiml.org).]



# Microbiological Tests

## 〈51〉 ANTIMICROBIAL EFFECTIVENESS TESTING

Antimicrobial preservatives are substances added to nonsterile dosage forms to protect them from microbiological growth or from microorganisms that are introduced inadvertently during or subsequent to the manufacturing process. In the case of sterile articles packaged in multiple-dose containers, antimicrobial preservatives are added to inhibit the growth of microorganisms that may be introduced from repeatedly withdrawing individual doses.

Antimicrobial preservatives should not be used as a substitute for good manufacturing practices or solely to reduce the viable microbial population of a nonsterile product or control the presterilization bioburden of multidose formulations during manufacturing. Antimicrobial preservatives in compendial dosage forms meet the requirements for *Added Substances* under *Ingredients and Processes* in the *General Notices*.

All useful antimicrobial agents are toxic substances. For maximum protection of patients, the concentration of the preservative shown to be effective in the final packaged product should be below a level that may be toxic to human beings.

The concentration of an added antimicrobial preservative can be kept at a minimum if the active ingredients of the formulation possess an intrinsic antimicrobial activity. Antimicrobial effectiveness, whether inherent in the product or whether produced because of the addition of an antimicrobial preservative, must be demonstrated for all injections packaged in multiple-dose containers or for other products containing antimicrobial preservatives. Antimicrobial effectiveness must be demonstrated for multiple-dose topical and oral dosage forms and for other dosage forms such as ophthalmic, otic, nasal, irrigation, and dialysis fluids (see *Pharmaceutical Dosage Forms* 〈1151〉).

This chapter provides tests to demonstrate the effectiveness of antimicrobial protection. Added antimicrobial preservatives must be declared on the label. The tests and criteria for effectiveness apply to a product in the original, unopened container in which it was distributed by the manufacturer.

### PRODUCT CATEGORIES

For the purpose of testing, compendial articles have been divided into four categories (see *Table 1*). The criteria of antimicrobial effectiveness for these products are a function of the route of administration.

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

**Table 1. Compendial Product Categories**

| Category | Product Description |
|---|---|
| 1 | Injections, other parenterals including emulsions, otic products, sterile nasal products, and ophthalmic products made with aqueous bases or vehicles. |
| 2 | Topically used products made with aqueous bases or vehicles, nonsterile nasal products, and emulsions, including those applied to mucous membranes. |
| 3 | Oral products other than antacids, made with aqueous bases or vehicles. |
| 4 | Antacids made with an aqueous base. |

## TEST ORGANISMS

Use cultures of the following microorganisms[1]: *Candida albicans* (ATCC No. 10231), *Aspergillus niger* (ATCC No. 16404), *Escherichia coli* (ATCC No. 8739), *Pseudomonas aeruginosa* (ATCC No. 9027), and *Staphylococcus aureus* (ATCC No. 6538). The viable microorganisms used in the test must not be more than five passages removed from the original ATCC culture. For purposes of the test, one passage is defined as the transfer of organisms from an established culture to fresh medium. All transfers are counted. In the case of organisms maintained by seed-lot techniques, each cycle of freezing, thawing, and revival in fresh medium is taken as one transfer. A seed-stock technique should be used for long-term storage of cultures. Cultures received from the ATCC should be resuscitated according to directions. If grown in broth, the cells are pelleted by centrifugation. Resuspend in 1/20th the volume of fresh maintenance broth, and add an equal volume of 20% (v/v in water) sterile glycerol. Cells grown on agar may be scraped from the surface into the 10% glycerol broth. Dispense small aliquots of the suspension into sterile vials. Store the vials in liquid nitrogen or in a mechanical freezer at no more than −50°. When a fresh seed-stock vial is required, it may be removed and used to inoculate a series of working cultures. These working cultures may then be used periodically (each day in the case of bacteria and yeast) to start the inoculum culture.

## MEDIA

All media used in the test must be tested for growth promotion. Use the microorganisms indicated above under *Test Organisms*.

## PREPARATION OF INOCULUM

Preparatory to the test, inoculate the surface of a suitable volume of solid agar medium from a recently revived stock culture of each of the specified microorganisms. The culture conditions for the inoculum culture are described in *Table 2* in which the suitable media are Soybean–Casein Digest or Sabouraud Dextrose Agar Medium (see *Microbial Enumeration Tests* ⟨61⟩ and *Tests for Specified Microorganisms* ⟨62⟩).

To harvest the bacterial and *C. albicans* cultures, use sterile saline TS, washing the surface growth, collecting it in a suitable vessel, and adding sufficient sterile saline TS to obtain a microbial count of about $1 \times 10^8$ colony-forming units (cfu) per mL. To harvest the cells of *A. niger*, use sterile saline TS containing 0.05% of polysorbate 80, and add sufficient sterile saline TS to obtain a count of about $1 \times 10^8$ cfu per mL.

Alternatively, the stock culture organisms may be grown in a suitable liquid medium (i.e., Soybean–Casein Digest Broth or Sabouraud Dextrose Broth) and the cells harvested by centrifugation, then washed and resuspended in sterile saline TS to obtain a microbial count of about $1 \times 10^8$ cfu per mL. [NOTE—The estimate of inoculum concentration may be performed by turbidimetric measurements for the challenge microorganisms. Refrigerate the suspension if it is not used within 2 hours.]

Determine the number of cfu per mL in each suspension, using the conditions of media and microbial recovery incubation times listed in *Table 2* to confirm the initial cfu per mL estimate. This value serves to calibrate the size of inoculum used in the test. The bacterial and yeast suspensions are to be used within 24 hours of harvest, but the fungal preparation may be stored under refrigeration for up to 7 days.

## PROCEDURE

The test can be conducted either in five original containers if sufficient volume of product is available in each container and the product container can be entered aseptically (i.e., needle and syringe through an elastomeric rubber stopper), or in five sterile, capped bacteriological containers of suitable size into which a sufficient volume of product has been transferred. Inoculate each container with one of the prepared and standardized inoculum, and mix. The volume of the suspension inoculum used is between 0.5% and 1.0% of the volume of the product. The concentration of test microorganisms that is added to the product (*Categories 1, 2,* and *3*) are such that the final concentration of the test preparation after inoculation is between $1 \times 10^5$ and $1 \times 10^6$ cfu per mL of the product. For *Category 4* products (antacids) the final concentration of the test preparation after inoculation is between $1 \times 10^3$ and $1 \times 10^4$ cfu per mL of the product.

The initial concentration of viable microorganisms in each test preparation is estimated based on the concentration of microorganisms in each of the standardized inoculum as determined by the plate-count method.

Incubate the inoculated containers at 22.5 ± 2.5°. Sample each container at the appropriate intervals specified in *Table 3*. Record any changes observed in appearance at these intervals. Determine by the plate-count procedure the number of cfu present in each test preparation for the applicable intervals (see *Procedure* under *Microbial Enumeration Tests* ⟨61⟩ and *Tests for Specified Microorganisms* ⟨62⟩). Incorporate an inactivator (neutralizer) of the specific antimicrobial in the plate count or in the appropriate dilution prepared for plating. These conditions are determined in the validation study for that sample based upon the conditions of media and microbial recovery incubation times listed in *Table 2*. Using the calculated concentrations of cfu per mL present at the start of the test, calculate the change in $\log_{10}$ values of



DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

**LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

**FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

**E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

**WHAT WILL YOU BUILD?** | **sales@docketalarm.com** | **1-866-77-FASTCASE**

fastcase®
Smarter legal research.